Pancreatic Cancer Lawyers for Users of Byetta, Januvia, Victoza
The product liability lawyers at Saiontz & Kirk, P.A. are reviewing potential Byetta cancer lawsuits, Januvia cancer lawsuits and Victoza cancer lawsuits for users of the popular diabetes drugs who have been diagnosed with pancreatic cancer.
Financial compensation may be available as a result of the drug makers’ failure to fully research the side effects of Byetta, Januvia and Victoza, or adequately warn about the risk of problems that may lead to the eventual diagnosis of cancer.
Byetta (exenatide), Januvia (sitagliptin) and Victoza (liraglutide) are part of a class of medications known as incretin mimetics, which have previously been linked to a potential risk of pancreatitis, or inflammation of the pancreas. Increasing evidence suggests that the medications may cause chronic, asymptomatic pancreatitis, which may ultimately lead to pancreas cancer from Byetta, Januvia or Victoza.
According to a study published in the medical journal Diabetes on March 17, researchers have confirmed that users of the medications are more likely to have increased pancreatic mass and precancerous cells, which are cells that may eventually evolve into tumors or pancreatic cancer.
On March 14, the FDA issued a Drug Safety Communication in response to the findings, indicating that they are evaluating the data and plan to conduct additional testing on the samples collected by researchers to further review the potential pancreatic toxicity associated with the medications.
Were You or a Loved One Diagnosed with Pancreatic Cancer After Using Byetta, Januvia or Victoza?
The FDA is investigating the side effects of the entire class of diabetes drug, known as incretin mimetics, which includes:
- exenatide: Byetta and Bydureon
- sitagliptin: Januvia, Janumet, Janumet XR and Juvisync
- liraglutide: Victoza
- saxagliptin: Onglyza, Kombiglyze XR
- alogliptin: Nesina, Kazano and Oseni
- linagliptin: Tradjenta and Jentadueto
Earlier this month, a study published in the medical journal JAMA Internal Medicine found that users of Byetta and Januvia were twice as likely as other diabetics to be hospitalized with acute pancreatitis.
As a result of the findings, researchers expressed concerns that this may ultimately cause a number of users of Byetta and Januvia to develop pancreatic cancer, calling for additional studies to be completed.
The prominent consumer watchdog group Public Citizen issued a press release late last week, highlighting the concerns about pancreatic cancer by pointing out that the drugs have no unique benefit for diabetics. While the group already filed a petition for a Victoza recall to be issued, the FDA has not acted on that request. The group indicates that it now appears likely that all medications from the family of incretin mimetics will have to be removed from the market, suggesting that a Byetta recall and Januvia recall may also be necessary.
Januvia, Victoza and Byetta Cancer Lawsuits
Although it appears that the drug makers knew or should have known about the potential risk of pancreatic cancer from Januvia, Byetta and Victoza, they failed to adequately warn consumers or the medical community, placing their desire for profits before the safety of patients using the medication.
As a result, the lawyers at Saiontz & Kirk, P.A. are reviewing potential lawsuits for individuals diagnosed with pancreatic cancer or severe pancreas injury after using the diabetes drugs.
Symptoms of pancreatic cancer can include:
- Fatigue and weariness
- Loss of appetite
- Nausea and Vomiting
- Upper abdomen pain
- Weight loss
To review a potential claim for yourself, a friend or family member, request a free consultation and claim evaluation. After speaking with one of our Januvia, Victoza and Byetta class action lawyers, there is no obligation to hire our law firm to pursue your claim. However, if you do decide to move forward with a case, our attorneys have the experience and resources to aggressively pursue a recovery for your injury from Byetta.